GOVX · Geovax Labs, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $18.12M | $23.71M | $20.72M | $9.12M | $15.55M | $2.44M |
| SG&A | $6.01M | $5.39M | $6.02M | $4.99M | $3.58M | $2.20M |
| Total Operating Expenses | $24.13M | $29.10M | $26.74M | $14.11M | $19.13M | $4.64M |
| D&A | $68.8K | $95.4K | $74.2K | $56.3K | $38.5K | $19.7K |
| Operating Income | ($21.64M) | ($25.14M) | ($26.74M) | ($14.03M) | ($18.75M) | ($2.82M) |
| Interest Expense | $0 | $21.4K | - | $0 | $1.3K | $143.5K |
| Income Tax | - | - | - | - | $0 | $0 |
| Net Income | ($21.46M) | ($24.99M) | ($25.97M) | ($14.02M) | ($18.57M) | ($2.96M) |
| EPS - Basic | ($22.40) | ($120.50) | ($357.25) | ($1140.00) | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.09M | $5.51M | $6.45M | $27.61M | $11.42M | $9.88M |
| Accounts Receivable | $0 | $659.4K | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $790.8K | $1.85M | $2.80M | $1.75M | $2.06M | $267.7K |
| Current Assets | $5.31M | $7.93M | $7.89M | $28.94M | $11.63M | $10.24M |
| Total Assets | $6.34M | $8.16M | $9.28M | $31.35M | $11.80M | $10.39M |
| Current Liabilities | $1.94M | $3.11M | $3.52M | $4.75M | $5.44M | $810.3K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $3.11M | - | - | $4.75M | $7.44M | $825.0K |
| Stockholders' Equity | $3.83M | $5.05M | $5.76M | $26.60M | $4.36M | $9.57M |
| Retained Earnings | ($150.82M) | ($129.36M) | ($104.36M) | ($78.40M) | ($64.38M) | ($45.81M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($21.47M) | ($24.68M) | ($25.17M) | ($19.03M) | ($11.20M) | ($2.75M) |
| Investing Cash Flow | ($27.6K) | ($20.7K) | ($48.9K) | ($134.3K) | ($47.7K) | ($156.8K) |
| Financing Cash Flow | $19.08M | $23.75M | $4.06M | $35.35M | $12.78M | $12.51M |
| CapEx | $27.6K | $20.7K | $48.9K | $134.3K | $47.7K | $156.8K |
| Free Cash Flow | ($21.50M) | ($24.70M) | ($25.22M) | ($19.16M) | ($11.24M) | ($2.91M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 1.00 | 0.99 | 0.97 | 1.37 | 0.61 | 0.98 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -338.5% | -306.4% | -279.7% | -44.7% | -157.4% | -28.5% |
| Return on equity | -561.2% | -495.0% | -450.6% | -52.7% | -425.8% | -30.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.74 | 2.55 | 2.24 | 6.10 | 2.14 | 12.63 |
| Quick ratio | 2.74 | 2.55 | 2.24 | 6.10 | 2.14 | 12.63 |
| Cash ratio | 1.59 | 1.77 | 1.83 | 5.82 | 2.10 | 12.20 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -1176.3x | - | - | -14576.8x | -19.6x |
| Equity multiplier | 1.66 | 1.62 | 1.61 | 1.18 | 2.70 | 1.09 |
| Liabilities / Assets | 0.49 | - | - | 0.15 | 0.63 | 0.08 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 13.9% | 6.0% | -90.6% | 25.2% | -565.5% | -18.7% |
| Net income growth (YoY) | 14.1% | 3.8% | -85.2% | 24.5% | -527.8% | -24.8% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 12.9% | 2.1% | -31.6% | -70.4% | -286.7% | -106.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -24.2% | -12.4% | -78.3% | 509.9% | -54.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing GeoVax Labs against the 5 most active filers in the same SIC group.